Design and Manufacture of Drug Delivery Platforms

处于评估早期阶段的药物通常只有少量可用。这种可用性的缺乏在试图评估产品的药代动力学和疗效时会带来困难，因为人们没有足够的材料在产品形式上重复多次。在了解原料药的分子结构如何用于预测关键行为(包括logP、溶解度和pKa)，以及如何使用释药片剂或植入物的配方设计和/或几何形状来控制药物溶出度方面的最新进展，将结合产生一种设计系统，使3D可打印固体剂型能够快速优化，为临床试验和早期评估做好准备。

Drugs in the early stages of assessment are usually only available in small amounts. This lack of availability presents difficulties when attempting to assess the pharmacokinetics and the efficacy of a product, since one does not have sufficient material to iterate many times over product form. Recent developments in understanding how the molecular structure of an API can be used to predict key behaviours including log P, solubility and pKa, and how the formulation design and/or geometry of a drug delivery tablet or implant can be used to control drug dissolution rate, will be combined to produce a design system that will enable rapid optimisation of 3D printable solid dosage forms ready for clinical trial and early stage assessment.